Table 1.

Immunophenotype of proliferating and differentiating MSCs




Proliferating MSCs

HB-EGF-treated MSCs

Preadipocytes

Preosteocytes

Prechondrocytes
CD105   ++   ++   ±   ±   ±  
CD73   ++   ++   ±   ±   ±  
CD106   ±   ±   ±   ±   ±  
CD29   ++   ++   ±   ±   ±  
CD44   +++   +++   +   +   +  
CD90   +++   +++   +   +   +  
CD45   -   -   -   -   -  
CD14   -   -   -   -   -  
CD11c   -   -   -   -   -  
CD123   -   -   -   -   -  
CD34   -   -   -   -   -  
CD31   -   -   -   -   -  
HB-EGF   -   -   -   -   -  
HER-1   +   -   -   -   -  
HER-4   -   -   -   -   -  
CD10   -   -   +   -   -  
CD56
 
-
 
-
 
-
 
+
 
-
 



Proliferating MSCs

HB-EGF-treated MSCs

Preadipocytes

Preosteocytes

Prechondrocytes
CD105   ++   ++   ±   ±   ±  
CD73   ++   ++   ±   ±   ±  
CD106   ±   ±   ±   ±   ±  
CD29   ++   ++   ±   ±   ±  
CD44   +++   +++   +   +   +  
CD90   +++   +++   +   +   +  
CD45   -   -   -   -   -  
CD14   -   -   -   -   -  
CD11c   -   -   -   -   -  
CD123   -   -   -   -   -  
CD34   -   -   -   -   -  
CD31   -   -   -   -   -  
HB-EGF   -   -   -   -   -  
HER-1   +   -   -   -   -  
HER-4   -   -   -   -   -  
CD10   -   -   +   -   -  
CD56
 
-
 
-
 
-
 
+
 
-
 

MSC immunophenotype have been analyzed by flow cytometry in standard conditions (proliferating cells), after 2-hour incubation with 25 ng/mL HB-EGF, and after culture with differentiation (adipogenic, osteogenic, chondrogenic) media. HB-EGF-treated MSCs lose HER-1 surface expression, which is restored a few hours after removing HB-EGF from the medium (data not shown). Results are expressed as intensity of expression (-, negative; ± weak expression; +, 1 log shift from negative control; ++, 2 log shifts from negative control; +++, 3 log shifts from negative control) and derive from 6 different experiments.

or Create an Account

Close Modal
Close Modal